TSC2 c.499T>C ;(p.W167R)

Variant ID: 16-2105420-T-C

NM_000548.3(TSC2):c.499T>C;(p.W167R)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.

Cancer Medicine
Weberpals, Johanne I JI; Pugh, Trevor J TJ; Marco-Casanova, Paola P; Goss, Glenwood D GD; Andrews Wright, Natalie N; Rath, Prisni P; Torchia, Jonathon J; Fortuna, Alexander A; Jones, Gemma N GN; Roudier, Martine P MP; Bernard, Laurence L; Lo, Bryan B; Torti, Dax D; Leon, Alberto A; Marsh, Kayla K; Hodgson, Darren D; Duciaume, Marc M; Howat, William J WJ; Lukashchuk, Natalia N; Lazic, Stanley E SE; Whelan, Doreen D; Sekhon, Harmanjatinder S HS
Publication Date: 2021-05

Variant appearance in text: TSC2: W167R
PubMed Link: 33811746
Variant Present in the following documents:
  • CAM4-10-3045-s001.xlsx, sheet 2
View BVdb publication page



TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias.

Endocrine-Related Cancer
Asprino, Paula Fontes PF; Linck, Rudinei Diogo Marques RDM; Cesar, Jônatas J; Freitas, Florêncio Porto FP; Koyama, Fernanda Christtanini FC; Riechelmann, Rachel Simões Pimenta RSP; Costa, Frederico Perego FP; Hoff, Paulo Marcelo Gehm PMG; Galante, Pedro Alexandre Favoretto PAF; Meyer, Diogo D; Camargo, Anamaria Aranha AA; Sabbaga, Jorge J
Publication Date: 2018-02

Variant appearance in text: TSC2: W167R
PubMed Link: 29167182
Variant Present in the following documents:
  • Main text
  • erc-25-L1.pdf
View BVdb publication page